China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s investigational new drug application (IND) for the multicentre Phase I ...

application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to commence ...

announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI363, a first-in-class PD-1 ...

By Kristin Robinson Senior Writer National Music Publishers’ Association (NMPA) president/CEO David Israelite joined the Association of Independent Music Publishers (AIMP) to give his annual ...

This is the NMPA's latest retaliation against Spotify since the streaming service reclassified its premium subscriptions as 'bundles' in March, lowering royalties for publishers. By Kristin ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new drug (IND) application to initiated the clinical ...

Morepen Laboratories Limited has received approval from the Center for Drug Evaluation (CDE) of China’s National Medical ...

China’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for ...

Clinical progress After receiving clearance from the CDE of China’s NMPA in May 2024, we commenced enrollment in a registrational Phase III clinical trial of olverembatinib for the treatment of ...